scholarly journals The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Danny Houtsma ◽  
Stefanie de Groot ◽  
Renee Baak-Pablo ◽  
Elma Meershoek -Klein Kranenbarg ◽  
Caroline M. Seynaeve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Available N ◽  
Cox Regression Analysis ◽  
Breast Cancer Outcome

AbstractThe PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer. However, it remains unclear whether this SNP is a predictive marker for tamoxifen efficacy or a prognostic marker for breast cancer outcome. The aim of this study was to examine the prognostic potential of this SNP in postmenopausal early breast cancer patients treated with adjuvant exemestane. Dutch postmenopausal patients randomised to 5 years of adjuvant exemestane of whom tissue was available (N = 807) were selected from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial database. The SNP rs2234693 in the ESR1 gene was genotyped on DNA from formalin-fixed paraffin embedded (FFPE) tumor tissue using Taqman assays and related to the primary endpoint disease-free survival (DFS) and secondary endpoint overall survival (OS). Survival analyses were performed using Cox regression analysis. In total 805 patients were included in the analyses (median follow up of 5.22 years) and genotypes were obtained in 97% of the samples. The variant T allele of PvuII in ESR1 (rs2234693) was associated with a better DFS (hazard ratio (HR) 0.689, 95% confidence interval (CI) 0.480–0.989, P = 0.044) in univariate analysis only, and a better OS in both univariate (HR 0.616, 95%, CI 0.411–0.923, P = 0.019) and multivariate analyses (HR 0.571, 95% CI 0.380–0.856, P = 0.007), consistent with a prognostic rather than a predictive drug response effect. Variation of PvuII in the ESR1 gene is related to OS in postmenopausal, early HR + breast cancer patients treated with exemestane in the TEAM study. Variation in the ESR1 gene may therefore be a prognostic marker of early breast cancer survival, and warrants further research.

scholarly journals Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages

2019 ◽  
Vol 10 (1) ◽  
pp. 38
Author(s):  
Nur Imroatul Mursyidah ◽  
Ami Ashariati ◽  
Etty Hary Kusumastuti
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
General Hospital ◽  
Cancer Survival ◽  
Stage Iv ◽  
Secondary Data ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Retrospective Case

ABSTRACTIntroduction: The aims of this study was to determine the differences of  breast cancer survival rate based on Pathological stages.Methods: This study was conducted with a retrospective case control design using secondary data from Dr. Soetomo General Hospital's medical records. The technique used to take the samples was purposive sampling. The sample was 45 breast cancer patients in Dr. Soetomo General Hospital In January 2015, that able to be contacted again and had a medical record in the oncology center in Dr. Soetomo General Hospital Surabaya. The variables studied is breast cancer survival based on the pathological stages.Results: Breast cancer patients at the stage of IIA have 100% 3-year survival rate, stage IIB by 83.3%, stage IIIA by 71.4%, stage IIIB by 53.8%, IIIC by 50%, and stage IV by 30%. With a comparison of the log-rank significance p = 0.104.Conclusion: The survival rate of breast cancer patients is lower in line with the increasing pathological stage of breast cancer.

scholarly journals CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unfavorable Prognostic Marker in Early Breast Cancer Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0121421 ◽  
Author(s):  
Leandro Marcelo Martinez ◽  
Vivian Labovsky ◽  
María de Luján Calcagno ◽  
Kevin Mauro Davies ◽  
Hernán Garcia Rivello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Stromal Cells ◽  
Primary Tumor ◽  
Breast Cancer Patients

scholarly journals Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival

2021 ◽  
Vol 10 ◽  
Author(s):  
Dai Zhang ◽  
Yi Zheng ◽  
Si Yang ◽  
Yiche Li ◽  
Meng Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survival ◽  
Cox Regression ◽  
Gene Signature ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Related Gene ◽  
Training Set ◽  
Cox Regression Analysis ◽  
Kaplan Meier

To identify a glycolysis-related gene signature for the evaluation of prognosis in patients with breast cancer, we analyzed the data of a training set from TCGA database and four validation cohorts from the GEO and ICGC databases which included 1,632 patients with breast cancer. We conducted GSEA, univariate Cox regression, LASSO, and multiple Cox regression analysis. Finally, an 11-gene signature related to glycolysis for predicting survival in patients with breast cancer was developed. And Kaplan–Meier analysis and ROC analyses suggested that the signature showed a good prognostic ability for BC in the TCGA, ICGC, and GEO datasets. The analyses of univariate Cox regression and multivariate Cox regression revealed that it’s an important prognostic factor independent of multiple clinical features. Moreover, a prognostic nomogram, combining the gene signature and clinical characteristics of patients, was constructed. These findings provide insights into the identification of breast cancer patients with a poor prognosis.

scholarly journals Changing Trends of Breast Cancer Survival in Sultanate of Oman

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Shiyam Kumar ◽  
Ikram A. Burney ◽  
Adel Al-Ajmi ◽  
Mansour S. Al-Moundhri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Survival Rates ◽  
Breast Cancer Survival ◽  
Lymph Node Status ◽  
Skin Involvement ◽  
Sultanate Of Oman ◽  
Breast Cancer Patients ◽  
Free Survival

Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate of Oman. Age at presentation was 47.41 years (SD12.88), with one-third of patients younger than 40 years. The majority of patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (), skin involvement (), and stage at presentation () were significantly associated with overall survival. Skin involvement at presentation (), T size (), lymph node status (), and stage () were strong predictors of relapse-free survival. Patients had a 5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identified in our previously published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have significantly improved.

Is Survival with Conservative Breast Therapy becoming Superior to that with Modified Radical Mastectomy alone for the Treatment of Early Breast Cancer in this Era?

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 24-24
Author(s):  
Mona M Sayed
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Disease Free Survival ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Modified Radical Mastectomy ◽  
Free Survival ◽  
Cox Regression Analysis ◽  
Disease Free

Purpose: This study aims to assess survival rates in early breast cancer patients treated by Conservative breast therapy (CBT), including radiotherapy, compared to those treated by modified radical mastectomy (MRM) alone. Methods: The South Egypt Cancer Institute and the Assiut University Oncology Department patients’ records, from January 2010 to December 2017, were searched for T1-2N0-1M0 breast cancer patients treated by CBT or MRM. Patients who didn’t receive chemotherapy were excluded to reduce the treatment variation. Results: The five-year locoregional disease free survival (LRDFS) was 97.3% for the CBT patients was and 98.0% for the MRM patients (P=.675). The five-year distant disease free survival (DDFS) was 93.6% for CBS and 85.7% for MRM (P=0.033). The DFS was 91.9% for the BCT patients and 85.3% for the MRM patients (P=0.045). The five-year OS was 98.2% for the CBT patients and 94.3% for the MRM patients, (P=0.02). By Cox regression analysis, the CBT resulted in significantly better OS, (p=0.018) and the (HR=0.350, 95% CI 0.146-0.837). The adjusted OS, estimated by the propensity-score based weights, remained superior in CBT than in MRM patients (p < 0.001). Conclusion: CBT resulted in better DDFS, DFS and OS than MRM. Future randomized trials are needed to confirm these findings and determine the cause.

Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 11074-11074
Author(s):  
Danny Houtsma ◽  
Stefanie de Groot ◽  
Tahar van der Straaten ◽  
Renee Baak-Pablo ◽  
Cock J.H. van der Velde ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Cancer Survival ◽  
Breast Cancer Survival

scholarly journals Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xu Liu ◽  
Dan Zheng ◽  
Yanqi Wu ◽  
Chuanxu Luo ◽  
Yu Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Information Management System ◽  
Elderly Group ◽  
Cancer Information ◽  
Breast Cancer Patients ◽  
Cox Regression Analysis

Abstract Background Despite the proportion of elderly breast cancer patients has been consistently increasing, the optimal treatment modalities for this population have not been well explored. We summarized the treatment outcomes of these patients in our hospital. Methods Older patients with early breast cancer were identified from the Breast Cancer Information Management System at West China Hospital, Sichuan University (2000–2019). We compared tumor characteristics and treatment outcomes between the older group (65–74 years old) and the elderly group (≥75 years old). The Kaplan-Meier and Cox regression analysis were conducted to determine significant prognostic factors. Results In total, 1094 patients were included. The median follow-up time for this cohort was 59 months. The majority of patients underwent surgery and benefited from surgical treatment. Elderly group patients were less likely to receive adjuvant chemotherapy or postmastectomy radiotherapy (PMRT) compared to the older group. However, adjuvant chemotherapy was associated with improved overall survival (OS) (hazard ratio [HR] 0.521, 95% confidence interval [CI] 0.284–0.955, P = 0.035). Subgroup analysis revealed that patients with grade III disease best benefited from adjuvant chemotherapy. PMRT offered a significant improvement in local disease control, but not in OS. Furthermore, endocrine therapy improved the OS of HR-positive patients (HR 0.440, 95%CI 0.261–0.741, P = 0.002), especially for cases aged 65–74 years. Also, receipt of trastuzumab in HER2-positive patients was associated with better OS (HR 0.168, 95%CI 0.029–0.958, P = 0.045). Conclusions Our findings suggest that surgery, adjuvant chemotherapy, endocrine and targeted therapy are associated with improved OS in older breast cancer patients. Moreover, clinicopathological characteristics should be comprehensively considered when making treatment decisions for these patients.

Sign in / Sign up

Export Citation Format

Share Document